ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Pre-Tax Income
ABL Bio Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Pre-Tax Income
-₩55.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Pre-Tax Income
₩576.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
14%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Pre-Tax Income
-₩89.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Pre-Tax Income
₩165.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Pre-Tax Income
₩115.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
44%
|
CAGR 10-Years
26%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Pre-Tax Income
₩36.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
47%
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Pre-Tax Income?
Pre-Tax Income
-55.5B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Pre-Tax Income amounts to -55.5B KRW.
What is ABL Bio Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-8%
Over the last year, the Pre-Tax Income growth was -1 998%. The average annual Pre-Tax Income growth rates for ABL Bio Inc have been -8% over the past three years , -8% over the past five years .
You don't have any saved screeners yet